<DOC>
	<DOCNO>NCT01012908</DOCNO>
	<brief_summary>The primary objective clinical trial demonstrate non-inferiority clinical development pancreatic enzyme Laboratory Bergamo ( Norzyme ® ) relation pancreatic enzyme Solvay Pharmaceuticals ( Creon ® ) , compare average amount lipid feces 72 hour 14 day treatment drug .</brief_summary>
	<brief_title>Clinical Non-Inferiority Pancreatic Enzymes ( Norzyme ® - Bergamo ) Compared To Creon ® ( Solvay Pharmaceutical ) Patients With Exocrine Pancreatic Insufficiency</brief_title>
	<detailed_description>As secondary objective assess follow parameter : - Incidence abdominal pain ; - Frequency flatus ; - Frequency bowel movement treatment ; - Consistency stool treatment ; - Amount medication use among treatment . All parameter measure base report patient specific diary .</detailed_description>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Patients must agree purpose study sign Informed Consent two way ; Be age 18 year ; Display chronic exocrine pancreatic insufficiency due chronic pancreatic , post surgical situation lead severe glandular disease ; Doing control clinical treatment enzyme replacement Creon ® 25,000 ( similar concentration lipase ) meal ; Agree record daily food intake phase 2 repeat diet phase 3 ; Present ability meet patient 's diary ; Be clinically compensate replacement therapy ; Must admit patient sex ; Must accept patient ethnicity . Cystic fibrosis ; Acute pancreatitis ; Participation experimental study ingestion experimental drug 12 month precede study ; Diabetes decompensated ; Regular use medication interfere action drug test : 4 week precede study medication interfere drug test week start study ; Any type treatment morbid obesity ; Abusive use alcohol three month precede study ; Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>